CD274 and melanoma: Background: A significant proportion of melanoma patients without as well as with pre-existing immunity fail to respond to checkpoint inhibitor therapy, indicating a therapeutic potential for combining PD-(L)1 therapy with immunomodulating agents in both immunophenotypes.